We also highlight pathways specific to one type of tissue – for KRAS mutant lung cancers, we find that pentose and glucoronate interconversions and linolenic acid metabolism are significantly enriched, and for TP53 mutant bladder cancer, we find an enrichment for core metabolic pathways involved in the citric acid cycle and glutamine metabolism. Here, KRAS is linked to lung carcinoma.